Ácido zoledrônico para pacientes com osteoporose com intolerância ou dificuldades de deglutição dos bisfosfonatos orais

Comissão Nacional de Incorporação de Tecnologias no SUS.
Brasília; CONITEC; jun. 2022.
Não convencional Português | BRISA | ID: biblio-1382316

Documentos relacionados

  1. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
  2. Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
  3. A Single-Center Prospective Study of 116 Women with Osteoporosis Treated with Zoledronic Acid Monitored by Electrocardiography for the Development of Cardiac Arrhythmia During the Acute Phase in China.
  4. Effect of oral zoledronate administration on bone turnover in older women.
  5. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
  6. Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service.
  7. [Side effects of osteoporosis treatments: how to explain them to patients?]
  8. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
  9. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
  10. Severe Acute Kidney Injury After Single-Dose Injection of Zoledronic Acid in an Elderly Patient.